RTP Mobile Logo
Novel Agents and Emerging Strategies in the Management of Gynecologic Cancers
Released June 2019

Faculty presentations from an independent satellite symposium during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer. Featuring perspectives from Dr Michael J Birrer, David M O’Malley, Matthew A Powell and Shannon N Westin. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

    The pace of oncology drug development has accelerated in recent years to previously unmatched levels. Fueled by an increased understanding of the biologic underpinnings of tumor development and progression, clinical research platforms largely focused on the evaluation of potential benefits with novel targeted therapeutics possessing unique mechanisms of action and safety profiles have led to improved outcomes in myriad large and rigorous clinical trials across many tumor types. The successes yielded by this rational approach to the design and evaluation of new therapies have in turn provided oncology healthcare professionals and patients with many additional and beneficial FDA-endorsed treatment options. Although this dynamic appears to be prevalent in many corners of oncology, recent advancements in the management of gynecologic cancers — including ovarian, cervical and endometrial cancer — have made it particularly relevant for this area of medicine. A plethora of extremely promising data sets related to the management of these diseases have recently emerged, providing significant enthusiasm that several more novel approaches may soon become available to practicing clinicians. Existing management algorithms for patients with these gynecologic cancers are poised for further change, and it is therefore critical that continuing education be offered to all practitioners involved in their care.

    This CME program developed from the proceedings of a satellite symposium held during the Society of Gynecologic Oncology’s 2019 Annual Meeting on Women’s Cancer features video slide presentations given by leading researchers with an expertise in gynecologic cancers. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies.


    • Review the mechanisms of action of, emerging efficacy data with and toxicity profiles of novel targeted agents under investigation in ovarian, endometrial and cervical cancer, and effectively prioritize clinical trial opportunities or expanded access programs for eligible patients.
    • Recall the biologic rationale for, published research data with and ongoing research evaluating the use of immune checkpoint inhibitors in the management of ovarian, endometrial and cervical cancer, and identify patients who may be eligible for this strategy in or outside of a protocol setting.
    • Appraise early research data and recently activated clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents or other immune checkpoint inhibitors for gynecologic cancers, and use this information to identify patients who may be eligible for study participation.
    • Recognize the incidence of folate receptor alpha overexpression in patients with gynecologic cancers, and consider the potential role of novel agents designed to exploit this therapeutic target.
    • Design and implement a plan of care to recognize and manage side effects and toxicities associated with novel and recently approved systemic therapies for patients with ovarian, endometrial and cervical cancer to support quality of life and continuation of therapy.
    • Counsel appropriately selected patients with ovarian, endometrial and cervical cancer about participation in ongoing research protocols.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Michael J Birrer, MD, PhD
    Director, O’Neal Comprehensive Cancer Center
    Professor of Medicine/Hematology and Oncology
    Evalina B Spencer Chair in Oncology
    The University of Alabama at Birmingham
    Birmingham, Alabama

    No relevant conflicts of interest to disclose.

    David M O’Malley, MD
    Medical Director, Gynecologic Oncology
    Director, Clinical Research, Gynecologic Oncology
    Co-Director, Gynecologic Oncology Phase I Program
    ORIEN Physician Liaison for OSUCCC – James
    The Ohio State University and The James Cancer Center
    Columbus, Ohio

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GOG Foundation Inc, Janssen Biotech Inc, Myriad Genetic Laboratories Inc, Tesaro; Consulting Agreements: AbbVie Inc, Ambry Genetics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, ImmunoGen Inc, Partnership for Health Analytic Research LLC, Tesaro; Contracted Research: Agenus Inc, Ajinomoto, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, EMD Serono Inc, Ergomed PLC, Exelixis Inc, Genentech, GlaxoSmithKline, GOG Foundation Inc, ImmunoGen Inc, Janssen Biotech Inc, Ludwig Institute for Cancer Research Ltd, Novartis, PRA Health Sciences, Regeneron Pharmaceuticals Inc, Stemcentrx, Syneos Health, Tesaro, TRACON Pharmaceuticals Inc; Data and Safety Monitoring Board: Marker Therapeutics Inc.

    Matthew A Powell, MD
    Professor and Chief
    Division of Gynecologic Oncology
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreements and Speakers Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Tesaro.

    Shannon N Westin, MD, MPH
    Associate Professor
    Director, Early Drug Development
    Department of Gynecologic Oncology and Reproductive Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Merck, Tesaro; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, Merck, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology, Tesaro; Contracted Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, Novartis, Roche Laboratories Inc, Tesaro; Data and Safety Monitoring Board/Committee: Syndax Pharmaceuticals Inc, Xenetic Biosciences Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Eisai Inc, Genmab and Seattle Genetics, ImmunoGen Inc and Tesaro.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: June 2019
    Expiration date: June 2020

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):